Physician profile
Richard Lam
NPI 1811925258
$7,212.97
in general payments reported to CMS, 2019-2025
31 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $544 · 2021: $634 · 2022: $1,181 · 2023: $1,123 · 2024: $1,632 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $12.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.89 |
| Education | $12.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,090.00 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $821.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $772.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $587.99 | 2021-2025 | Lynparza |
| Amgen INC. | $534.91 | 2019-2023 | Prolia |
| Dendreon Pharmaceuticals LLC | $467.67 | 2020-2024 | Provenge |
| Sumitomo Pharma America, INC. | $403.71 | 2023-2025 | Orgovyx, Gemtesa |
| Novartis Pharmaceuticals Corporation | $381.98 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $377.17 | 2020-2025 | Prolaris, Myrisk |
| Merck Sharp & Dohme LLC | $251.89 | 2020-2025 | Lynparza, Keytruda |
| Blue Earth Diagnostics | $194.44 | 2019-2025 | Posluma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.35 | 2021-2022 | |
| Abbvie INC. | $168.02 | 2019-2025 | |
| Astellas Pharma US INC | $161.26 | 2019-2024 | Xtandi, Veozah |
| Progenics Pharmaceuticals, INC. | $152.97 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $101.57 | 2022-2025 | |
| Accord Healthcare, INC. | $82.47 | 2023-2025 | |
| Genzyme Corporation | $68.45 | 2019-2023 | |
| Exact Sciences Corporation | $63.60 | 2023-2025 | Cologuard Collection Kit |
| Foundation Medicine, INC. | $62.65 | 2023 | Foundationone Liquid Cdx |
| Coherus Oncology, INC. | $53.69 | 2020-2024 | |
| Mylan Institutional INC. | $44.45 | 2019 | |
| Myovant Sciences INC. | $43.09 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $22.80 | 2019 | |
| Spectrum Pharmaceuticals INC. | $19.89 | 2023 | Rolvedon |
| Avadel Specialty Pharmaceuticals, LLC | $19.08 | 2019 | |
| Mannkind Corporation | $16.11 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.10 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $15.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2023 | Seglentis, Livalo |
| Endo Pharmaceuticals INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.